Frontiers in Medical Science Research, 2023, 5(8); doi: 10.25236/FMSR.2023.050801.
Feng Wan1, Ke Chen3, Fei Chen4, Xiangkun Tao4, Xia Liu2, Cheng Peng1
1State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China
2Department of Clinical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai, China
3Department of Traditional Chinese Medicine, People's Hospital of Xinjin District, Chengdu, Sichuan, China
4Psychologic Medicine Science, Chongqing Medical University, Chongqing, China
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus which has caused an ongoing pandemic since 2020. It is estimated that 15% patients may develop severe pneumonia, 5% develop acute respiratory distress syndrome (ARDS), septic shock, and multiple organ failure. Anisodamine hydrobromide is a muscarinic receptor antagonist, and also shows anti-inflammatory effect. It has been approved in China to be used in patients with septic shock, organophosphorus poisoning and smooth muscle spasm. We describe three patients with positive results of NATs for SARS-CoV-2, persistent shortness of breath, reduced oxygen saturation and impaired physical endurance even after long-term routine treatments, who were diagnosed with Corona Virus Disease 2019 (COVID-19) infection. After the patients were additionally administrated anisodamine hydrobromide (20 mg twice daily) intravenously for 5 consecutive days based on the original routine treatments, the conditions of COVID-19 infection were rapidly improved, with ameliorated shortness of breath, coughing and sputum, increased oxygen saturation, and improved physical endurance. No obvious adverse effect was observed. Anisodamine hydrobromide might hold great prospect for potential clinical applications in treating COVID-19 patients and improving their conditions.
COVID-19, anisodamine hydrobromide, muscarinic receptor antagonists, cholinergic anti-inflammatory pathway, pro-inflammatory factors
Feng Wan, Ke Chen, Fei Chen, Xiangkun Tao, Xia Liu, Cheng Peng. Treatment of COVID-19 Patients with Anisodamine Hydrobromide: Three Cases Report and Literature Review. Frontiers in Medical Science Research (2023) Vol. 5, Issue 8: 1-6. https://doi.org/10.25236/FMSR.2023.050801.
[1] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China[J]. Jama, 2020, 323(11):1061-1069.
[2] The Novel Coronavirus Pneumonia Emergency Response Epidemiology T. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020[J]. China CDC Wkly, 2020, 2(8):113-122.
[3] Unal Enginar A. Arthritis following COVID-19 vaccination: report of two cases[J]. Int Immunopharmacol, 2021, 101(Pt B):108256.
[4] Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal[J]. J Heart Lung Transplant, 2020,39(5):405-407.
[5] Mouffak S, Shubbar Q, Saleh E, et al. Recent advances in management of COVID-19: A review[J]. Biomed Pharmacother, 2021, 143:112107.
[6] Poupko JM, Baskin SI, Moore E. The pharmacological properties of anisodamine[J]. J Appl Toxicol, 2007, 27(2):116-121.
[7] Liu C, Shen FM, Le YY, et al. Antishock effect of anisodamine involves a novel pathway for activating alpha7 nicotinic acetylcholine receptor[J]. Crit Care Med, 2009, 37(2):634-641.
[8] Jing YL, Wang YL, Sun Y, et al. Experimental research of prevention and therapy effect of anisodamine on acute respiratory distress syndrome (ARDS)[J]. Chin J Appl Phys, 2009, 25(4):557-560.
[9] Yu Y, Zhu C, Hong Y, et al. Effectiveness of anisodamine for the treatment of critically ill patients with septic shock: a multicentre randomized controlled trial[J]. Crit Care, 2021, 25(1):349.
[10] Zhang S, Chang AM, Li CF, et al. Mechanism of the therapeutic effect of anisodamine in disseminated intravascular coagulation: study of platelet adhesion and aggregation, malondialdehyde, thromboxane B2, 6-keto-prostaglandin F1 alpha, and microcirculation[J]. Exp Hematol, 1987, 15(1):65-71.
[11] Qin Z, Xiang K, Su DF, et al. Activation of the Cholinergic Anti-Inflammatory Pathway as a Novel Therapeutic Strategy for COVID-19[J]. Front Immunol, 2020, 11:595342.
[12] Su J, Liu Z, Liu C, et al. Network Pharmacology Integrated Molecular Docking Reveals the Mechanism of Anisodamine Hydrobromide Injection against Novel Coronavirus Pneumonia[J]. Evid Based Complement Alternat Med, 2020:5818107.
[13] Wei W, Kong N, Liu MZ, et al. Anisodamine potently inhibits SARS-CoV-2 infection in vitro and targets its main protease[J]. Biochem Biophys Res Commun, 2022, 616:8-13.
[14] Ruan QR, Zhang WJ, Hufnagl P, et al. Anisodamine counteracts lipopolysaccharide-induced tissue factor and plasminogen activator inhibitor-1 expression in human endothelial cells: contribution of the NF-kappa b pathway[J]. J Vasc Res, Jan-Feb 2001, 38(1):13-19.
[15] Chai J, Yang H, Sheng Z, et al. Anisodamine in prevention and treatment of sepsis of severely burned patients[J]. Chin J Surg, 2000, 38(9):686-689.
[16] Guoshou Z, Chengye Z, Zhihui L, et al. Effects of high dose of anisodamine on the respiratory function of patients with traumatic acute lung injury[J]. Cell Biochem Biophys, 2013, 66(2):365-369.
[17] Bai S, Fu X, Gu X, et al. Intracoronary administration of different doses of anisodamine in primary percutaneous coronary intervention: protective effect in patients with ST-segment elevation myocardial infarction[J]. Coron Artery Dis, 2016, 27(4):302-310.
[18] Xing K, Fu X, Jiang L, et al. Cardioprotective Effect of Anisodamine Against Myocardial Ischemia Injury and its Influence on Cardiomyocytes Apoptosis[J]. Cell Biochem Biophys, 2015, 73(3):707-716.
[19] Qian J, Zhang JM, Lin LL, et al. A combination of neostigmine and anisodamine protects against ischemic stroke by activating α7nAChR[J]. Int J Stroke, 2015, 10(5):737-744.
[20] Li YF, Xu BY, An R, et al. Protective effect of anisodamine in rats with glycerol-induced acute kidney injury[J]. BMC Nephrol, 2019, 20(1):223.